相似文献
1
Role of Stem Cells in Pathophysiology and Therapy of Spondyloarthropathies-New Therapeutic Possibilities?
Int J Mol Sci. 2017 Dec 28;19(1):80. doi: 10.3390/ijms19010080.
2
Insights into the pathology and treatment of spondyloarthritis: from the bench to the clinic.
Semin Arthritis Rheum. 2008 Oct;38(2):83-100. doi: 10.1016/j.semarthrit.2007.10.007. Epub 2007 Dec 31.
3
Role of Interleukin- (IL-) 17 in the Pathogenesis and Targeted Therapies in Spondyloarthropathies.
Mediators Inflamm. 2018 Feb 12;2018:2403935. doi: 10.1155/2018/2403935. eCollection 2018.
4
Tumor necrosis factor alpha blockade treatment down-modulates the increased systemic and local expression of Toll-like receptor 2 and Toll-like receptor 4 in spondylarthropathy.
Arthritis Rheum. 2005 Jul;52(7):2146-58. doi: 10.1002/art.21155.
5
Interferon-γ contributes to HLA-B27-associated unfolded protein response in spondyloarthropathies.
J Rheumatol. 2012 Mar;39(3):574-82. doi: 10.3899/jrheum.101257. Epub 2012 Jan 15.
6
Secukinumab for rheumatology: development and its potential place in therapy.
Drug Des Devel Ther. 2016 Jun 24;10:2069-80. doi: 10.2147/DDDT.S105263. eCollection 2016.
7
Galectin-1 and galectin-3 expression in equine mesenchymal stromal cells (MSCs), synovial fibroblasts and chondrocytes, and the effect of inflammation on MSC motility.
Stem Cell Res Ther. 2017 Nov 2;8(1):243. doi: 10.1186/s13287-017-0691-2.
8
Spondyloarthropathies: an overview.
Intern Med J. 2002 Jan-Feb;32(1-2):40-6.
9
Treatment of spondyloarthropathy: the potential for agents other than TNF inhibitors.
Curr Opin Rheumatol. 2013 Jul;25(4):455-9. doi: 10.1097/BOR.0b013e3283620177.
引用本文的文献
1
Bone marrow adipocytes: key players in vascular niches, aging, and disease.
Front Cell Dev Biol. 2025 Aug 7;13:1633801. doi: 10.3389/fcell.2025.1633801. eCollection 2025.
2
Breaking boundaries in ankylosing spondylitis: how innovative cell therapies reshape immunity, drive cutting-edge advances, and face future challenges.
Front Immunol. 2025 Jul 11;16:1613502. doi: 10.3389/fimmu.2025.1613502. eCollection 2025.
3
Microbiome dysbiosis in spinal pathology: Mechanisms, evidence, and research limitations.
Brain Spine. 2025 May 2;5:104272. doi: 10.1016/j.bas.2025.104272. eCollection 2025.
4
Evaluation of preclinical efficacy of human umbilical cord mesenchymal stem cells in ankylosing spondylitis.
Front Immunol. 2023 Mar 30;14:1153927. doi: 10.3389/fimmu.2023.1153927. eCollection 2023.
5
Aberrant lncRNA-mRNA expression profile and function networks during the adipogenesis of mesenchymal stem cells from patients with ankylosing spondylitis.
Front Genet. 2022 Oct 3;13:991875. doi: 10.3389/fgene.2022.991875. eCollection 2022.
6
Efficacy and Safety of Mesenchymal Stem Cell Transplantation in the Treatment of Autoimmune Diseases (Rheumatoid Arthritis, Systemic Lupus Erythematosus, Inflammatory Bowel Disease, Multiple Sclerosis, and Ankylosing Spondylitis): A Systematic Review and Meta-Analysis of Randomized Controlled Trial.
Stem Cells Int. 2022 Mar 24;2022:9463314. doi: 10.1155/2022/9463314. eCollection 2022.
7
[Hyperactivation of PI3K/AKT/mTOR signal pathway impairs TNF-α-induced autophagy in mesenchymal stem cells from patients with ankylosing spondylitis].
Nan Fang Yi Ke Da Xue Xue Bao. 2022 Feb 20;42(2):272-277. doi: 10.12122/j.issn.1673-4254.2022.02.15.
8
Modulatory Impact of Adipose-Derived Mesenchymal Stem Cells of Ankylosing Spondylitis Patients on T Helper Cell Differentiation.
Cells. 2021 Jan 30;10(2):280. doi: 10.3390/cells10020280.
9
IL-17A and TNF Modulate Normal Human Spinal Entheseal Bone and Soft Tissue Mesenchymal Stem Cell Osteogenesis, Adipogenesis, and Stromal Function.
Cells. 2021 Feb 6;10(2):341. doi: 10.3390/cells10020341.
10
Modulation of T-Cell Activation Markers Expression by the Adipose Tissue-Derived Mesenchymal Stem Cells of Patients with Rheumatic Diseases.
Cell Transplant. 2020 Jan-Dec;29:963689720945682. doi: 10.1177/0963689720945682.
本文引用的文献
1
M2 polarization of monocytes in ankylosing spondylitis and relationship with inflammation and structural damage.
APMIS. 2017 Dec;125(12):1070-1075. doi: 10.1111/apm.12757. Epub 2017 Oct 3.
2
Increased frequency of circulating CD19+CD24hiCD38hi B cells with regulatory capacity in patients with Ankylosing spondylitis (AS) naïve for biological agents.
PLoS One. 2017 Jul 6;12(7):e0180726. doi: 10.1371/journal.pone.0180726. eCollection 2017.
3
Bone marrow-derived stem/stromal cells and adipose tissue-derived stem/stromal cells: Their comparative efficacies and synergistic effects.
J Biomed Mater Res A. 2017 Sep;105(9):2640-2648. doi: 10.1002/jbm.a.36089. Epub 2017 May 17.
4
Functional defects in CD4 CD25 FoxP3 regulatory cells in ankylosing spondylitis.
Sci Rep. 2016 Nov 30;6:37559. doi: 10.1038/srep37559.
5
IL-10-produced by human transitional B-cells down-regulates CD86 expression on B-cells leading to inhibition of CD4+T-cell responses.
Sci Rep. 2016 Jan 22;6:20044. doi: 10.1038/srep20044.
6
Stem cells - biological update and cell therapy progress.
Clujul Med. 2015;88(3):265-71. doi: 10.15386/cjmed-483. Epub 2015 Jul 1.
7
Human mesenchymal stem cells and derived extracellular vesicles induce regulatory dendritic cells in type 1 diabetic patients.
Diabetologia. 2016 Feb;59(2):325-33. doi: 10.1007/s00125-015-3808-0. Epub 2015 Nov 23.
8
Imbalance Between Bone Morphogenetic Protein 2 and Noggin Induces Abnormal Osteogenic Differentiation of Mesenchymal Stem Cells in Ankylosing Spondylitis.
Arthritis Rheumatol. 2016 Feb;68(2):430-40. doi: 10.1002/art.39433.
9
Mesenchymal stem cell therapy for osteoarthritis: current perspectives.
Stem Cells Cloning. 2015 Aug 28;8:117-24. doi: 10.2147/SCCAA.S68073. eCollection 2015.
10
Ca(2+) Signalling in Endothelial Progenitor Cells: Friend or Foe?
J Cell Physiol. 2016 Feb;231(2):314-27. doi: 10.1002/jcp.25126.
Zotero 插件
